Clinical trial registry record

A Study of Everolimus in the Treatment of Neurocognitive Problems in Tuberous Sclerosis

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Unknown.
Evidence
Registered phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated January 30, 2018.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT01954693
Last registry update
January 30, 2018
Status
Unknown
Phase
Phase 2
Sponsor
Cardiff University
Enrollment
48
Countries
United Kingdom
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 2
Study design
RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
Evidence population
Human clinical study registration
Participants
48
Population
ALL · 16 Years to 60 Years
Duration
2012-06-01 to 2018-08-06
Intervention
Placebo; Everolimus (RAD001)
Comparator
Placebo
Outcomes measured
List Learning test (from the BIRT Memory and Information Processing Battery) — 6 months; Complex Figure test (from the BIRT Memory and Information Processing Battery) — 6 months; CANTAB - Stockings of Cambridge (SOC) — 6 months; CANTAB - Spatial Working Memory (SWM) — 6 months; Telephone search dual task (from the Test of Everyday Attention) — 6 months; CANTAB - Rapid Visual Information Processing Battery (RVIP) — 6 months; CANTAB - Spatial Span (SSP) — 6 months; CANTAB - Attentional Set-shifting (IDED) — 6 month; Verbal Fluency /Controlled Oral Word Association Test (COWAT) — 6 months; Cancellation task — 6 months; Symptom Checklist 90R (SCL-90R) — 6 months; Quality of Life in Epilepsy (QOLIE) — 6 months; Liverpool Seizure Severity Scale (LSSS) — 6 months; Vineland Adaptive Behavior Scales-II (VABS-II) (survey form) — 6 months; Social Responsiveness Scale - Adult version (SRS-A) — 6 months; Social communication questionnaire (SCQ) — 6 months; National Adult Reading Test (NART) — 6 months
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Rapamycin · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

rapamycin
Read the original source →Export JSON